Providence, RI [Brown University] BЂ "ItBЂ ™ is not surprising that efforts medicineBЂ ™ to combat bacterial infections is often described as an arms race. When developing new drugs to fight infections, bacterial goal is always to deterrence. Especially ingenious weapon in the arsenal of bacterial drug pump end. These pumps are proteins located in membranes of bacteria that can recognize and eliminate drugs that have broken membranes. In some cases bacterial pumps have become so advanced, they can recognize and eliminate drugs with very different structures and mechanisms. BЂњThis is a real problem in clinical settings, especially for bacterial pathogens acquire genes encoding the end of the strattera dosing pump, which operates on multiple antibiotics, BЂ "says Jason Sello, assistant professor of chemistry at Brown University. BЂњIn worst case, the bacteria can go all the way from drugs likely resistant to five or six different drugs through the acquisition of a single gene. BЂ "
Jason Sello new way of dealing with drug-resistant bacteria: BЂњIf drugs pumped prohibited, the bacteria are susceptible to drugs again. BЂ "
therefore has two options: Make all new and expensive antibiotics or find a way to bypass the pump. Sello and his team chose the latter. In an article published in the magazine
Bioorganic and Medical Chemistry, the team said it opened a new connection C-disabled DIPEPTIDES called BU-005, to get around the family of drugs pumped associated with gram-positive bacteria that include dangerous MRSA and tuberculosis strain. Until this discovery, C-disabled DIPEPTIDES is known to work only with the end of the pump family of related gram-negative bacteria. BЂњIf drugs pumped prohibited, the bacteria are susceptible to drugs again BЂ «Sello said. BЂњThis approach is interesting because it was necessary to detect the end of the pump inhibitors, but not completely new types of antibacterial drugs. BЂ "
Recently a company called MPEX Pharmaceuticals found that concrete with lids DIPEPTIDES can block the outflow pumps RND family, who are responsible for most of the drug resistance in gram-negative bacteria. One of these compounds developed in the MPEX came in first phase of clinical trials of FDA. Sello and his collaborators investigated whether C-disabled DIPEPTIDES can clog the pump end of another family of drugs called supersimeystva main facilitator (MFS), due mainly to gram-positive bacteria. Brown believes that the team is new and perhaps more powerful C-disabled Dipeptide blockers pump end can be detected. Since it is impossible to predict where the C-disabled DIPEPTIDES will drain pump blockers, they synthesized a set of structurally diverse with lids DIPEPTIDES and selection for its connection with new or improved activities. This usually four to five stages. SelloBЂ ™ s group reduced that by two steps, using a method that is used in other methods of chemical reaction known as Uhi. Using this approach, the team was able to prepare dozens of C-disabled DIPEPTIDES. They evaluated the ability of each compoundBЂ ™ and blocked two pumped in bacteria
Streptomyces coelicolor, a relative human pathogen Mycobacterium tuberculosis
and which is opposed to chloramphenicol, one of the oldest antimicrobials. From the collection of about 100 ° C caps DIPEPTIDES that they are prepared and audited, the group found, BU-005. New Connection excitation researchers, because it prevented completion pump MFS family from deportation chloramphenicol. So far, structurally related C-disabled DIPEPTIDES only reported to prevent the expulsion of chloramphenicol other families end drug pump. BЂњOur conclude that C-disabled dipeptide prevent pumped as gram-positive and gram-negative bacteria should increase interest in these compounds, "Sello said." In addition, our simplified synthetic route has to do with medical chemistry of this class of compounds is much easier. BЂ "
Two Brown students, Daniel Hrynvald BЂ ™ 12 and Jessica Wroten BЂ ™ 11, helped carry out the study and the authors of the paper. Hrynvald joined the first year after Sello. BЂњThis project was the first real immersion I was in chemistry research at a high level BЂ "says Hrynvald, Madison, Wisconsin. BЂњIt was an amazing opportunity to be able to use the tools of synthetic chemistry to solve problems of molecular biology. It was definitely one of the most appealing aspects of my experience at Brown. BЂ «
Babajide Okandeji, who received his doctorate in May last year and represents a new quality control products chemist corporation water in Taunton, Mass., is the first author paperBЂ ™ s. Brown University funded the work. Hrynvald was supported program Royce Fellows. Wroten was financed Brown University Undergraduate Teaching and Research Fellowship (UTRA) in summer 2010. .
No comments:
Post a Comment